[1]闫娜娜,李雪萍,李 亚,等.FGF23与心血管疾病的研究进展[J].医学信息,2019,32(19):43-46.[doi:10.3969/j.issn.1006-1959.2019.19.014]
　YAN Na-na,LI Xue-ping,LI Ya,et al.Progress in Research on FGF23 and Cardiovascular Diseases[J].Journal of Medical Information,2019,32(19):43-46.[doi:10.3969/j.issn.1006-1959.2019.19.014]
点击复制

FGF23与心血管疾病的研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年19期
页码:
43-46
栏目:
综述
出版日期:
2019-10-01

文章信息/Info

Title:
Progress in Research on FGF23 and Cardiovascular Diseases
文章编号:
1006-1959（2019）19-0043-04
作者:
闫娜娜1; 李雪萍1; 李 亚2; 薛苗苗1; 高梦琪1; 宋 梅1; 郭 剑3; 许刚柱2
（1.西安医学院临床医学院，陕西 西安 710021；2.西安医学院第一附属医院内分泌科，陕西 西安 710003；3.陕西省人民医院医院内分泌科，陕西 西安 710068）
Author(s):
YAN Na-na1; LI Xue-ping1; LI Ya2; XUE Miao-miao1; GAO Meng-qi1; SONG Mei1; GUO Jian3; XU Gang-zhu2
(1.School of Clinical Medicine,Xi'an Medical College,Xi'an 710021,Shaanxi,China;2.Department of Endocrinology,the First Affiliated Hospital of Xi'an Medical College,Xi'an 710003,Shaanxi,China;3.Department of Endocrinology,Shaanxi Provincial People's Hospital,Xi'an 710068,Shaanxi,China)
关键词:
成纤维细胞因子23; 钙磷代谢; 心血管疾病; 传导通路
Keywords:
Fibroblast factor 23; Calcium and phosphorus metabolism; Cardiovascular disease; Conduction pathway
分类号:
R54；R743
DOI:
10.3969/j.issn.1006-1959.2019.19.014
文献标志码:
A
摘要:
成纤维细胞生长因子23（FGF23）是骨细胞和骨原细胞分泌产生的一种激素样调磷因子，在肾脏及甲状旁腺中调节磷酸盐稳态和维生素D代谢。近年来发现FGF23对心血管疾病的发生发展及其预后有重要意义，有望成为心血管疾病防治的新靶点，本文就FGF23在心血管疾病的作用机制做一综述。
Abstract:
Fibroblast growth factor 23 (FGF23) is a hormone-like phosphorous factor secreted by bone cells and osteogenic cells, which regulates phosphate homeostasis and vitamin D metabolism in the kidney and parathyroid glands. In recent years, FGF23 has been found to be important for the development and prognosis of cardiovascular diseases, and it is expected to become a new target for prevention and treatment of cardiovascular diseases. This article reviews the mechanism of FGF23 in cardiovascular diseases.

参考文献/References:

[1]Chen Q,Zhang Y,Ding D,et al.Associations between serum calcium, phosphorus and mortality among patients with coronary heart disease[J].Eur J Nutr,2018,57(7):2457-2467. [2]Mohammadi M,Olsen SK,Ibrahimi OA.Structural basis for fibroblast growth factor receptor activation[J].Cytokine Growth Factor Rev,2005,16(2):107-137. [3]Yamashita H,Yamashita T,Miyamoto M,et al.Fibroblast growth factor(FGF)-23in patients with primary hyperparathyroidism[J].Eur J Endocrinol,2004,151(1):55-60. [4]Courbebaisse M,Lanske B.Biology of fibroblast growth factor 23 from physiology to pathology[J].Cold Spring Harb Perspect Med,2018,8(5):a031260. [5]Zununi Vahed S,Nikasa P,Ardalan M.Klotho and renal fibrosis[J].Nephro-urology Monthly,2013,5(5):946-948. [6]Leifheit-Nestler M,Kirchhoff F,Nespor J,et al.Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts[J].Nephrol Dial Transplant,2018,33(10):1722-1734. [7]Nassiri AA,Hakemi MS,Safar-Pour R,et al.Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis[J].Transl Int Med,2016,4(3):135-141. [8]Nakahara T,Kawai-Kowase K,Matsui H,et al.Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells[J].Atherosclerosis,2016(253):102-110. [9]邹新蓉,王小琴,吴艳萍,等.FGF23对慢行肾脏病5期患者桡动脉血管钙化的影响[J].中国妇幼健康研究,2017,28(S3):9. [10]Chen YX,Huang C,Duan ZB,et al.Klotho/FGF23 axis mediates high phosphate-induced vascular calcification in vascular smooth muscle cells via Wnt7b/β-catenin pathway[J].Kaohiung J Med Sci,2019,35(7):393-400. [11]Zheng S,Zhang S,Song Y,et al.MicroRNA-297a regulates vascular calcification by targeting fibroblast growth factor 23[J].Iran J Basic Med Sci,2016,19(12):1331-1336. [12]Tuzun D,Oguz A,Aydin MN,et al.Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes?[J].Arch Endocrinol Metab,2018,62(5):506-513. [13]Hu X,Ma X,Luo Y,et al.Contribution of fibroblast growth factor 23 to Framingham risk score for identifying subclinical atherosclerosis in Chinese[J].Nutr Metab Cardiovasc Dis,2017,27(2):147-153. [14]Schumacher D,Alampour-Rajabi S,Ponomariov V,et al.Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation[J].Cytokine,2018(111):106-111. [15]陈晶晶,冯高科,易欣,等,血清成纤维细胞生长因子23与心房颤动的关系[J].中国循证心血管医学杂志,2019,11(4):414-417. [16]Dong QB,Tang YH,Wang WX,et al.Relationship between FGF23/FGFR4 expression in atrial tissue and atrial fibrosis in patients with atrial fibrillation[J].National Medical Journal of China,2018,98(13):1003-1007. [17]Dong Q,Li S,Wang W,et al.FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways[J].J Cell Physiol,2019. [18]Schumacher D,Alampour-Rajabi S,Ponomariov V,et al.Cardiac FGF23:new insights into the role and function of FGF23 after acute myocardial infarction.Cardiovasc Pathol[J].Cardiovasc Pathol,2019(40):47-54. [19]Takahashi H,Ozeki M,Fujisaka T,et al.Changes in Serum Fibroblast Growth Factor 23 in Patients With Acute Myocardial Infarction[J].Circ J,2018,82(3):767-774. [20]Heineke J,Molkentin JD.Regulation of cardiac hypertrophy by intracellular signalling pathways[J].Nat Rev Mol Cell Biol,2006,7(8):589-600. [21]Mhatre KN,Wakula P,Klein O,et al.Crosstalk between FGF23- and angiotensin II-mediated Ca2+signaling in pathological cardiac hypertrophy[J].Cell Mol Life Sci,2018,75(23):4403-4416. [22]Grabner A,Schramm K,Silswal N,et al.FGF23/FGFR4-mediated left ventricular hypertrophy is reversible[J].Sci Rep,2017,7(1):1993. [23]Maaten JM,Voors AA,Damman K,et al.Fibroblast growth factor 23 is related to profiles indicating volume overload,poor therapy optimization and prognosis in patients with new-onset and worsening heart failure[J].J Cardiol,2018(253):84-90. [24]Akhabue E,Vu TT,Vaidya A,et al.Growth Factor-23,Heart Failure Risk,and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension:The MESA Study[J].Am J Hypertens,2019,32(1):18-25. [25]李俊霞,林强,俞国庆,等.慢性肾脏病患者血清FGF23水平对血压的影响[A]//中国中西医结合学会会议论文集[C].2018. [26]Wang X,Shapiro JI.Evolving concepts in the pathogenesis of uraemic cardiomyopathy[J].Nat Rev Nephrol,2019,15(3):159-175. [27]Cai P,Peng Y,Li L,et al.Fibroblast growth factor 23(FGF23)gene polymorphisms are associated with essential hypertension risk and blood pressure levels in Chinese Han population.Clin Exp Hypertens[J].Clin Exp Hypertens,2018,40(7):680-685.

相似文献/References:

[1]邹 鑫,刘秀娟,余燕燕.血液透析对MHD患者血清FGF-23水平与 钙磷代谢的影响[J].医学信息,2018,31(09):119.[doi:10.3969/j.issn.1006-1959.2018.09.036]
　ZOU Xin,LIU Xiu-juan,YU Yan-yan.Effect of Hemodialysis on Serum FGF-23 Level and Calcium and Phosphorus Metabolism in MHD Patients[J].Journal of Medical Information,2018,31(19):119.[doi:10.3969/j.issn.1006-1959.2018.09.036]
[2]程 颖,卢 文.尿毒症透析患者心血管钙化及左心室肥厚影响因素的研究[J].医学信息,2019,32(09):91.[doi:10.3969/j.issn.1006-1959.2019.09.029]
　CHENG Ying,LU Wen.Study on the Influencing Factors of Cardiovascular Calcification and Left Ventricular Hypertrophy in Uremic Dialysis Patients[J].Journal of Medical Information,2019,32(19):91.[doi:10.3969/j.issn.1006-1959.2019.09.029]
[3]梁宏丽.基于Omaha系统的延续性护理模式对维持性血液透析患者行为依从性和钙磷代谢的影响[J].医学信息,2020,33(23):164.[doi:10.3969/j.issn.1006-1959.2020.23.048]
　LIANG Hong-li.Influence of Omaha System-based Continuous Nursing Model on Behavior Compliance and Calcium and Phosphorus Metabolism of Maintenance Hemodialysis Patients[J].Journal of Medical Information,2020,33(19):164.[doi:10.3969/j.issn.1006-1959.2020.23.048]

更新日期/Last Update: 2019-10-01